NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb Company (NYSE:BMY) announced today that Elizabeth Mily has been appointed Executive Vice President, Strategy & Business Development, effective March 30, 2020. In this role, Mily will oversee company strategy and all business development activities, including strategic partnerships, mergers and acquisitions, as well as other strategic initiatives.
“Elizabeth is an accomplished leader in investment banking and health care M&A, and I look forward to the important role she will play in sourcing external innovation to drive our vision of transforming patients’ lives through science,” said Giovanni Caforio, chairman and chief executive officer, Bristol Myers Squibb. “I am excited to welcome her to Bristol Myers Squibb as we position the company for continued growth through high performing brands, upcoming new product launches, an exciting pipeline, and the financial strength to pursue innovation for the next wave of new medicines.”
Mily will report to Caforio and will be a member of the Bristol Myers Squibb leadership team.
Mily joins Bristol Myers Squibb from Barclays, where she was the Managing Director and Chair of the Global Lifesciences group in the global healthcare unit. During her career she has executed over $200 billion in completed M&A advisory assignments and has advised on an extensive amount of debt, equity and equity-linked financings. Prior to joining Barclays, Mily served as Head of Corporate Strategy and Development at Thermo Fisher Scientific. Prior to that she spent 16 years at Goldman, Sachs & Co. where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.